RT Journal
A1 Reiffel JA
T1 EQuivalence of generic and brand-name drugs for cardiovascular disease
JF JAMA
JO JAMA
YR 2009
FD April 22
VO 301
IS 16
SP 1654
OP 1656
DO 10.1001/jama.2009.522
UL http://dx.doi.org/10.1001/jama.2009.522
AB 
To the Editor: Although the observations of Dr Kesselheim and colleagues1 are generally accurate, the authors oversimplified the issue and did not adequately consider all of the evidence. They largely grouped the material they reviewed into clinical trials and editorials. The former were appropriately given more weight in the authors' conclusions. However, case report material in some editorials as well as in articles that were not included2 (such as reports of serious arrhythmic recurrences, proarrhythmic events, and deaths in association with formulation substitution of an antiarrhythmic drug) was ignored.